Tuberculosis: the drug development pipeline at a glance

Area of Science:

• Medicinal Chemistry
• Microbiology
• Pharmacology

Background:

• Tuberculosis (TB) remains a leading cause of bacterial infection mortality worldwide, causing 1.8 million deaths annually.
• The emergence of drug-resistant strains and HIV co-infections has created an urgent need for new anti-tuberculosis drugs.
• Despite this need, no new anti-TB molecules have reached the market in the past 40 years.

Purpose of the Study:

• To review current small molecules targeting Mycobacterium tuberculosis.
• To detail the chemical synthesis, mechanism of action, and in vitro/in vivo activities of these compounds.
• To present available clinical data for novel anti-TB drug candidates.

Main Methods:

• Literature review of preclinical and clinical studies on small molecules for TB treatment.
• Analysis of chemical synthesis pathways for novel anti-TB agents.
• Compilation of in vitro, in vivo, and clinical trial data for drug candidates.

Main Results:

• A robust pipeline of potential new TB treatments is now available, with several compounds in clinical trials or preclinical development.
• Existing antibiotics like gatifloxacin, moxifloxacin, metronidazole, and linezolid are being evaluated for TB treatment.
• Novel chemical entities and analogues of known TB drugs, including TMC207, BTZ043, and PA-824, show promising activity against sensitive and resistant M. tuberculosis strains.

Conclusions:

• The development of new anti-tuberculosis drugs is advancing with numerous promising small molecules in the pipeline.
• These compounds offer potential new treatment options for both drug-sensitive and drug-resistant TB.
• Further clinical evaluation is crucial to bring these novel therapies to patients.